Skip to content

Advertisement

  • Poster presentation
  • Open Access

Immunodominant Anti-Gag SLYNTVATL Responses in HIV-patients With More Than Five Years of HAART-induced Undetectable Plasma Viremia

  • 1Email author,
  • 1,
  • 2,
  • 2 and
  • 3
Retrovirology20052(Suppl 1):P1

https://doi.org/10.1186/1742-4690-2-S1-P1

Published: 8 December 2005

Keywords

  • Successful Therapy
  • Median Time
  • Treated Patient
  • Flow Cytometer
  • Untreated Patient

Background

HIV-specific CD8+ T-cells in the peripheral blood diminish in most patients after the initiation of highly active antiretroviral therapy (HAART). However, examples of de novo appearance of HIV-specific CD8+ T-cells in patients with long-term successful therapy have also been described. The aim of our study was to determine the frequency and absolute counts of Gag-specific CD8+ T-cells in the peripheral blood of HIV-patients with more than 5 years of treatment-induced undetectable viremia and compare it with non-symptomatic untreated chronically-infected persons.

Materials and methods

The study enrolled 15 untreated HIV-patients (median CD4 T-cells count 323.5 cells/μL, median percentage of CD4+ T-cells 17.3%) and 15 HIV-patients who have maintained undetectable plasma viremia (<50 copies of HIV-1 RNA/mL) for more than 5 years (median time on HAART 6.7 years, range 5 to 7 years, median CD4+ T-cell count 544 cells/μL, median percentage of CD4+ T-cells 24.3%). Percentages of Gag-specific CD8+ T-cells in the peripheral blood of our patients were determined by using iTAg™ MHC class I tetramers (A*0201) specific for SLYNTVATL (Beckman Coulter Immunomics Operations, USA) on FC500 flow cytometer (Beckman Coulter, USA). Absolute counts of Gag-specific CD8+ T-cells were determined by using Flow-count Fluorospheres (Beckman Coulter, USA).

Results

Gag-specific CD8+ T-cells were detected in 12/15 (80%) of untreated HIV-patients and in 9/15 (66%) of treated HIV-patients with > 5 years of undetectable viremia. Percentages of Gag-specific CD8+ T-cells in ranged between 0.1 and 1.1% in untreated patients and between 0.1–0.7% in treated patients. Untreated HIV-patients had between 1 and 9 Gag-specific CD8 T-cells/μL of blood. HIV-patients with more than 5 years of undetectable viremia had between 1–6 Gag-specific CD8+ T-cells/μL of blood.

Conclusion

Gag-specific CD8+ T-cells are detectable in some patients who have been successfully treated with HAART for more than 5 years. The frequency and absolute counts of Gag-specific CD8+ T-cells in patients with more than 5 years of successful HAART are different compared with untreated patients. These findings are relevant for the analysis of immune reconstitution following long-term successful HAART.

Notes

Authors’ Affiliations

(1)
Division of Cellular Immunology, University Hospital for Infectious Diseases, Zagreb, Croatia
(2)
Department for Research and Development, Institute of Immunology, Zagreb, Croatia
(3)
Croatian Refferal Center for AIDS, University Hospital for Infectious Diseases, Zagreb, Croatia

Copyright

© The Author(s) 2005

Advertisement